What Researchers Did
Researchers reported on four cases of mucormycosis in patients who received bone marrow transplants for thalassemia and reviewed 18 similar cases from medical literature.
What They Found
Among 711 patients who had bone marrow transplants for thalassemia, four developed mucormycosis. This infection was the main cause of death for three of these four patients. Only one of the four patients experienced partial recovery from sinonasal mucormycosis after receiving aggressive antifungal treatment combined with hyperbaric oxygen therapy.
What This Means for Canadian Patients
For Canadian patients with thalassemia undergoing bone marrow transplantation, mucormycosis is a rare but serious infection. This report suggests that a combination of aggressive antifungal therapy and hyperbaric oxygen treatment might offer a chance for partial recovery in some cases of this severe infection.
Canadian Relevance
No direct Canadian connection identified. Mucormycosis is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
As a case report, this study involves a very small number of patients and does not provide strong evidence for the effectiveness of hyperbaric oxygen therapy.